This editorial refers to 'Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, When comparing the trials of more vs. less statin, the high-dose statin regimens provided an additional 15% risk reduction in major vascular events (95% CI 11 -18%, P , 0.001), including coronary death and non-fatal myocardial infarction, over and above the benefit conferred by the low-dose regimen. In PROVE-IT TIMI 22, intensive statin therapy with atorvastatin 80 mg was superior to pravastatin 40 mg in patients with a recent acute coronary syndrome (ACS), resulting in a 16% reduction in hazard for the composite endpoint of death, myocardial infarction (MI), unstable angina requiring hospitalization, revascularization, and stroke. 4 Furthermore, high-dose atorvastatin was more likely to achieve the dual therapeutic target of LDL ,70 mg/dL and C-reactive protein ,2 mg/L than standard dose pravastatin in this secondary prevention population. 
thermore, high-dose atorvastatin was more likely to achieve the dual therapeutic target of LDL ,70 mg/dL and C-reactive protein ,2 mg/L than standard dose pravastatin in this secondary prevention population. 5 Despite their proven efficacy and extreme utility in achieving LDL targets, however, the use of standard and high-dose statins can be limited in some patients due to side effects. Because HMG-CoA reductase inhibition can cause depletion of antioxidants that are enriched in metabolically active tissues, such as muscles, there can be tissue-specific side effects of therapy, including myalgias, weakness, myopathy, and, rarely, rhabdomyolysis leading to renal failure and possibly death. A meta-analysis of 18 statin trials with 71 108 patients showed that the number needed to harm (NNH) for serious events such as creatinine phosphokinase .10× ULN (upper limit of normal) or rhabdomyolysis was quite large (NNH ¼ 3400 and NNH ¼ 7428, respectively) while the number needed to treat (NNT) with statin to reduce the risk of a clinical cardiovascular event was quite low at only 27 patients. 6 Clinical factors that predispose patients to a higher incidence of side effects include being female, older age, low body weight, pre-existing renal or hepatic dysfunction, multiorgan disease, and concurrent alcohol use. 7 Although the incidence of serious side effects is rare (myopathy ,1/10 000 compared with placebo), there are a number of patients who experience myalgias or muscle pain without elevation in muscle enzymes, which has an incidence of 5-10% in practice, 7 and can limit compliance. Because their primary target is in the liver, statins can also cause elevations in liver function tests (LFTs), mostly resulting in reversible and asymptomatic transaminase elevations, without evidence of direct hepatotoxicity. Additionally, an increased risk of diabetes has also been reported. Patients who experience such side effects are therefore unable to take statins. Although it is difficult to obtain exact numbers, one estimate reports that of the 71 million patients with hyperlipidaemia in the USA, only 34 million are treated. 8 Of these patients, 12 million have uncontrolled lipid levels and 1.4 million are refractory or 'intolerant' to statins. Clinicians face significant challenges in treating such 'statin-intolerant' patients, and treatment options are limited. Because achieved LDL remains the principal determinant of outcomes, regardless of the drug used, other options to lower LDL should be pursued in this population. Visser and Stroes have now presented Phase II data from a randomized double-blind placebo-controlled trial of mipomersen in high-risk patients who are unable to take statins. 9 Mipomersen is a novel antisense oligonucleotide which inhibits the synthesis of apolipoprotein B-100 (apoB-100) and is a long-lasting injectable drug that is metabolized both hepatically and renally. ApoB-100 is the primary structural apolipoprotein of LDL particles and is involved in secretion of very low-density lipoprotein (VLDL) and delivery of LDL to tissues. By inhibiting synthesis of this integral protein in cholesterol secretion and delivery, mipomersen can dramatically reduce the concentration of circulating LDL, making this drug a highly appealing option for patients who are unable to tolerate statins ( Figure 1) . Indeed, the first in human studies of this compound in 36 volunteers with mild dyslipidaemia reduced apoB by a maximum of 50% (P ¼ 0.002), which corresponded to an LDL reduction of 35% (P ¼ 0.001), with effects being maintained even 3 months after the last dose. 10 Doses in this trial ranged from 50 to 400 mg and were administered mostly subcutaneously (initial loading dose, weeks 2, 3, and 4) except for one dose which was given intravenously (week 1). Several subsequent studies in mildly hyperlipidaemic subjects, 11 subjects on background statin therapy, 12 and subjects with heterozygous familial hypercholesterolaemia 12 revealed similar results, with dosedependent reductions in LDL, ranging from 21% to 61%, and in apoB, ranging from 19% to 61%. Safety data were notable for a high incidence of local injection site reactions and dose-dependent persistent increases in LFTs ≥3× upper limit of normal (ULN) of 6-18% in all of these studies; the percentage of patients who had persistent elevations was higher in the setting of a background statin. 12 In the study of Visser and Stroes, 33 hypercholesterolaemic subjects who were established as statin intolerant by being unable to tolerate at least two different statins due to side effects and met high risk criteria for ACS, as defined by heterozygous familial hypercholesterolaemia or the NCEP-ATP III criteria, were randomized in a 2:1 ratio to mipomersen (n ¼ 21) vs. placebo (n ¼ 12). This drug was administered with matching placebo at a dose of 200 mg weekly via subcutaneous injection for 26 weeks, followed by a prolonged monitoring period of 6 months. There was a 47% reduction (+18%, P , 0.001), from 6.3 + 2.4 to 3.3 + 1.9 mmol/L, in the primary efficacy endpoint of LDL 2 weeks after the last dose of mipomersen, compared with placebo, with a similar reduction of 46% (+20%, P , 0.001) in mean apoB levels. Notably, there was a differential effect on LDL particles, with maximal lowering of the small particles as compared with the larger ones. Additional lipid parameters were also affected by mipomersen, with a reduction in triglycerides of 27% and an increase in HDL of 8%. Adverse effects, however, were quite common and included injection site reactions in 95% of the patients in the mipomersen arm and 83% in the placebo arm, although no patients discontinued study treatment due to injection site reactions. On the other hand, only six patients discontinued treatment prematurely due to side effects (four in the mipomersen arm due to flu-like symptoms, malaise, myalgia, and reversible transaminase elevations ≥10× ULN; and one in the placebo arm due to diarrhoea and one due to MI), resulting in a .80% compliance rate. Elevated transaminases above the ULN were much more common with mipomersen (81% vs. 25%), with no Editorial concurrent elevation in total bilirubin, alkaline phosphatase, or prothrombin time. These elevations were inversely correlated with the degree of apoB suppression, suggesting that those who had a more potent response may be higher risk for side effects. Following discontinuation of therapy, LFTs returned to normal in all patients and there was no evidence of direct or permanent hepatotoxicity. In the 14 out of 21 patients in the mipomersen arm who had increases in alanine aminotransferase (ALT) at least ≥2× ULN, however, hepatic magnetic resonance spectroscopy revealed an intrahepatic triglyceride (IHTG) content ranging from 0.8% to 47.3% (median 24.4%), with 12 out of 14 meeting the definition for intrahepatic steatosis (IHTG) (P ¼ 0.022 compared with placebo). Remarkably, the correlation coefficient between elevated ALT and apoB levels (r ¼ -0.644) was very similar to the correlation coefficient between highest IHTG content and apoB levels (r ¼ -0.699), suggesting that these side effects are linked and may have common pathways. Following discontinuation of mipomersen, all patients showed stability or regression of IHTG.
These results provide evidence on the efficacy and safety of mipomersen in lowering LDL-cholesterol and apoB in statinintolerant patients. Statin-intolerant patients are notoriously difficult for the clinician to treat because of limited pharmacological options. In these patients, providers can attempt statin treatment at low doses, administer therapy only three times a week instead of daily, or switch between statins to minimize the incidence of adverse effects. In addition, multiple alternative agents, such as ezetemibe, bile acid-binding resins, fibrates, and niacin, can also be prescribed (Table 1) , but the degree of LDL lowering with these interventions remains modest. There are newer agents, such as PCSK9 inhibitors, that are currently in clinical trials, but have not yet received Food and Drug Administration (FDA) approval. Finally, lifestyle changes such as diet and exercise, which can lower LDL, should be especially emphasized in this patient population. Nonetheless, approaches to treat the statin-intolerant patient remain limited and relatively ineffective, resulting in a high-risk patient population that usually ends up remaining undertreated as a result of its inability to receive the first-line therapy.
In this regard, mipomersen offers an intriguing alternative. However, there is a highly significant incidence of adverse effects related both to the administration (injection site reactions) and the mechanism (IHTG accumulation, LFT abnormalities) of the drug that must be noted. Also notable is that the incidence of IHTG was higher in the present study compared with previous studies of shorter duration. 13, 14 Although the mechanisms of steatosis in apoB inhibition (down-regulation of hepatic fatty acid synthase and increased fatty acid oxidation) do not appear to confer the same degree of risk for progression to fibrosis and cirrhosis as other hepatosteatotic conditions, such as nonalcoholic fatty liver disease, the long-term effects of increased intrahepatic fat content remain undetermined. Therefore, when choosing mipomersen therapy, extra vigilance will be needed to monitor the patient closely for LFT abnormalities and fatty acid accumulation in the liver. Since these adverse effects appear to be duration and dose dependent, intermittent dosing or lower doses of mipomersen may also be a strategic option in statin-intolerant patients who might be at higher risk for these adverse effects. Furthermore, as with any injectable drug, injection site reactions can be significant, which may also limit the maximally tolerated dosing interval of this drug. In the statin era in which we currently practice, mipomersen will never become first-line therapy for hyperlipidaemia, but, given its efficacy, it holds promise as a second-or third-line agent for the particularly challenging high-risk patients who cannot tolerate statins to achieve their LDL targets.
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